Valsartan: Discovery, Development, Safety and Pharmacovigilance
Valsartan is an orally administered angiotensin II type 1 (AT1) receptor blocker developed by Ciba-Geigy/Novartis and marketed under the Diovan name. Initial US approval occurred in 1996 [1]. Its lifecycle connects three distinct evidence systems: pharmacological and cardiovascular trials establishing therapeutic benefit, routine safety surveillance for predictable renin–angiotensin-system effects, and the 2018 discovery of nitrosamine contamination in certain manufacturers' products. The last is a manufacturing-quality risk, not an intrinsic pharmacodynamic effect of pure valsartan [1,2].
- Valsartan: Discovery, Development, Safety and Pharmacovigilance
- 1. Discovery and pharmacological rationale
- 2. Development, commercialisation and indication evolution
- 3. Evidence in hypertension: the VALUE trial
- 4. Heart failure: Val-HeFT
- 5. Post-myocardial infarction: VALIANT
- 6. Predictable haemodynamic and electrolyte risks
- 7. Fetal toxicity: a high-consequence class effect
- 8. Interactions and therapeutic combinations
- 9. Rare hypersensitivity and other adverse reactions
- 10. Manufacturing quality became a major safety issue in 2018
- 11. Operational management of a nitrosamine-related product complaint
- 12. Routine pharmacovigilance: case follow-up by phenotype
- 13. Signal management and QPPV oversight
- 14. Regulatory learning from the valsartan crisis
- 15. Key takeaways
- References
- Regulatory Note
1. Discovery and pharmacological rationale
The renin–angiotensin–aldosterone system (RAAS) regulates vascular tone, sodium handling, aldosterone release and haemodynamic responses to changing blood volume. Angiotensin II acting at the AT1 receptor contributes to vasoconstriction, aldosterone secretion and cardiovascular remodelling. Valsartan was developed as a nonpeptide, selective AT1 receptor antagonist, enabling blockade of this signalling pathway without inhibiting angiotensin-converting enzyme (ACE) [1,3].
This difference from ACE inhibitors is clinically important. Valsartan does not directly inhibit the enzyme that degrades bradykinin, helping explain a different cough profile from ACE inhibitors. However, the absence of ACE inhibition does not eliminate RAAS-associated risks of hypotension, reduced glomerular filtration under susceptible conditions, hyperkalaemia or fetal injury. It also does not make angioedema impossible [1].
Valsartan is an active compound, not a prodrug requiring metabolic activation. It is highly protein-bound and is eliminated substantially through biliary/faecal routes; a relatively modest fraction of a dose is recovered as metabolites [1]. For pharmacovigilance, these properties matter less than baseline renal haemodynamics, volume status, concomitant medicines and the reason for treatment.
2. Development, commercialisation and indication evolution
The medicine emerged during a period in which nonpeptide angiotensin-receptor antagonists offered an alternative approach to blocking the RAAS. The originator product was associated with Ciba-Geigy and subsequently Novartis following the 1996 merger that formed Novartis. The first US valsartan approval was in 1996 [1]. Brand and generic presentations, including fixed-dose combinations, later expanded exposure across primary care and cardiovascular medicine.
The current US generic product information identifies hypertension, heart failure and post-myocardial-infarction treatment in appropriately defined patients [1]. Regulatory wording and paediatric age limits vary across marketed labels and revision dates; for example, a US label revised February 2026 does not use the same paediatric lower age boundary as an older 2020 label [1,4]. Never collapse different label versions into one supposed universal rule.
Valsartan is also one constituent of sacubitril/valsartan, an angiotensin receptor–neprilysin inhibitor combination. The combination has distinct pharmacology, dosing, indication evidence, regulatory labelling and adverse-event context. Sales, outcome-trial effects and all adverse events of sacubitril/valsartan cannot automatically be assigned to the valsartan ingredient alone. The current article concerns single-ingredient valsartan unless otherwise specified.
3. Evidence in hypertension: the VALUE trial
The Valsartan Antihypertensive Long-term Use Evaluation (VALUE) study randomised 15,245 patients with hypertension and high cardiovascular risk to regimens based on valsartan or amlodipine, following participants for a mean 4.2 years. The primary composite cardiac endpoint occurred in 810 valsartan-treated patients (10.6%) and 789 amlodipine-treated patients (10.4%), hazard ratio 1.04 (95% CI 0.94–1.15; p=0.49) [5].
The two regimens did not achieve identical blood pressure. At one month, the amlodipine-based regimen lowered pressure approximately 4.0/2.1 mm Hg more, complicating mechanistic comparisons [5]. Thus the study did not establish that valsartan uniquely reduces the primary cardiac composite more than amlodipine. Early blood-pressure control and treatment titration remain essential context for interpreting observed event differences.
A later post-hoc matching analysis compared patients with similar achieved systolic pressures [6]. That analysis can inform hypotheses but does not restore randomisation after matching and must not replace the prespecified main-trial conclusion.
4. Heart failure: Val-HeFT
In Val-HeFT, 5,010 patients with symptomatic chronic heart failure were randomised to valsartan or placebo on background treatment. All-cause mortality was similar between groups. The combined mortality-and-morbidity endpoint was reduced by 13.2% relatively, driven largely by fewer heart-failure hospitalisations; hospitalisation occurred in 13.8% versus 18.2% [7].
The distinction between composite morbidity benefit and all-cause mortality is critical. It would be inaccurate to report the relative composite reduction as a demonstrated mortality reduction. Background treatment also differs from contemporary guideline-directed heart-failure therapy, limiting direct transportability to every modern regimen.
Subgroup analyses of patients not receiving ACE inhibitors suggested important benefits but represent a smaller selected subset [8]. Subgroup findings should be described as such rather than treated as independent replication of a primary randomised comparison.
5. Post-myocardial infarction: VALIANT
VALIANT enrolled 14,703 patients following myocardial infarction complicated by heart failure, left ventricular dysfunction or both. Patients were assigned to valsartan, captopril or the combination. Over median 24.7 months, deaths numbered 979/4,909 with valsartan, 958/4,909 with captopril and 941/4,885 with combination treatment. Valsartan met the prespecified noninferiority criterion against captopril for mortality; combining the two agents increased adverse reactions without improving survival [9].
These results are not a general endorsement of dual RAAS blockade. In fact, the combination arm illustrates the trade-off between mechanistic plausibility and observed clinical harm. In practice, the risk of hypotension, hyperkalaemia and renal impairment must be assessed alongside the indication and co-medications.
| Study | Population | Principal finding | Important boundary |
|---|---|---|---|
| VALUE | High-risk hypertension | No significant difference in primary cardiac composite vs amlodipine regimen | Early BP separation |
| Val-HeFT | Chronic symptomatic HF | Combined mortality/morbidity reduced; mortality alone similar | Historic background therapy |
| VALIANT | Recent complicated MI | Valsartan noninferior to captopril for mortality | Combination increased adverse events |
The three trials used different comparators, endpoints and background treatment. Their relative effects must not be ranked as though they were one head-to-head experiment [5,7,9].
6. Predictable haemodynamic and electrolyte risks
Hypotension and volume depletion
AT1 receptor blockade lowers vascular resistance and may cause symptomatic hypotension, particularly in patients with volume depletion, high-dose diuretics, vomiting or diarrhoea, or advanced heart failure. Clinical evaluation should include blood-pressure trajectory, orthostatic symptoms, recent changes in diuretics and fluid intake, and evidence of decompensated disease [1].
A fall in blood pressure is an intended pharmacodynamic effect; syncope, shock or symptomatic hypotension is a different clinical event. A valid safety narrative must identify the event and its consequences rather than treating all measured pressure reductions as adverse reactions.
Renal function deterioration
Angiotensin II helps maintain glomerular filtration pressure in some low-perfusion states by constricting the efferent arteriole. RAAS blockade can therefore produce a creatinine increase, especially in bilateral renal artery stenosis, dehydration, advanced heart failure or concurrent nephrotoxic treatment [1]. The mechanism is haemodynamic and should not automatically be coded as direct structural kidney toxicity.
For suspected acute kidney injury, document baseline and serial creatinine, eGFR, urine output, blood pressure, intercurrent infection, fluid balance, diuretics, NSAIDs and renal vascular disease. A small early creatinine change and severe oliguric injury are not equivalent. Clinical management must reflect severity and the patient's indication.
Hyperkalaemia
Reduced aldosterone signalling can diminish renal potassium excretion. The risk increases with kidney impairment, potassium supplements, potassium-containing salt substitutes, potassium-sparing diuretics and other RAAS-modifying drugs [1]. An elevated potassium result should be interpreted with specimen quality, haemolysis, kidney function, ECG and repeat measurements when appropriate. Serious hyperkalaemia can cause life-threatening arrhythmia and requires urgent clinical evaluation.
These effects are related but not interchangeable: hypotension may occur without hyperkalaemia, and potassium elevation can occur without symptomatic hypotension. Signal detection and follow-up should retain distinct medical phenotypes.
7. Fetal toxicity: a high-consequence class effect
US valsartan product information carries a boxed warning for fetal toxicity. Drugs acting directly on the RAAS can cause fetal injury or death, particularly with exposure during the second and third trimesters; the label directs discontinuation as soon as pregnancy is detected [1]. This is not a theoretical class precaution that should be downplayed because maternal blood pressure is controlled.
A pregnancy-exposure report should establish gestational age at conception and at first/last valsartan dose, indication, maternal kidney disease, blood pressure, alternative antihypertensives, fetal renal and amniotic-fluid findings, ultrasound monitoring, birth outcome and infant renal function when available. An adverse outcome is not automatically attributable to valsartan if exposure timing or other causes are unclear; conversely, uncertainty must not delay appropriate clinical care.
The current US label also advises against breastfeeding during valsartan treatment [1]. Local SmPC recommendations, paediatric use and reproductive counselling should be checked against the actual product and jurisdiction.
8. Interactions and therapeutic combinations
NSAIDs can impair renal perfusion and reduce antihypertensive effectiveness; the combination is particularly consequential in older or volume-depleted patients and when a diuretic is also present. Lithium concentrations may rise with RAAS blockers, creating a toxicity risk requiring clinical and laboratory assessment. Potassium supplements and potassium-sparing agents increase the risk of hyperkalaemia [1].
Dual RAAS inhibition, including some ACE inhibitor/ARB or aliskiren combinations, increases risks of renal dysfunction, hypotension and potassium elevation. US labels contraindicate aliskiren coadministration with valsartan in patients with diabetes [1]. The specific prohibition and monitoring language must be read from the current local label rather than inferred from an older one.
| Exposure pattern | Main safety concern | Priority follow-up |
|---|---|---|
| Valsartan + diuretic during dehydration | Symptomatic hypotension and acute kidney injury | Fluid losses, BP, creatinine, dose chronology |
| Valsartan + NSAID | Renal dysfunction and reduced BP response | NSAID start date, kidney function, BP |
| Valsartan + spironolactone/potassium | Hyperkalaemia | Potassium, renal function, ECG, supplements |
| Valsartan + lithium | Increased lithium exposure and toxicity | Lithium concentration, renal function, neurological signs |
| Valsartan + other RAAS blocker | Hypotension, kidney injury, hyperkalaemia | Exact agents, indication, lab chronology |
A fixed-dose combination with hydrochlorothiazide or amlodipine adds the second active ingredient's risks and its own regulatory labelling. A safety report should capture all constituents and the actual dispensed product [1].
9. Rare hypersensitivity and other adverse reactions
Angioedema has been reported with angiotensin receptor blockers. Although bradykinin effects differ from ACE inhibitors, new tongue, facial or laryngeal swelling demands emergency assessment. Collect the timing, anatomical distribution, airway involvement, prior ACE inhibitor reactions, other possible triggers and treatment [1].
Dizziness, fatigue and gastrointestinal complaints appear in product information, with frequencies dependent on the indication and trial population. Cough is generally less prominent than with ACE inhibitors but can occur for unrelated reasons. Reporters should avoid inferring a mechanistic cause solely from a familiar symptom.
10. Manufacturing quality became a major safety issue in 2018
In 2018, regulators identified N-nitrosodimethylamine (NDMA) in valsartan active substance manufactured by Zhejiang Huahai Pharmaceuticals. Subsequent investigations identified other nitrosamines, including N-nitrosodiethylamine (NDEA), in some angiotensin-receptor blocker products. NDMA and NDEA are regarded as probable human carcinogens based substantially on animal and mechanistic evidence [2,10–12].
The central distinction is contaminated batches versus valsartan as a pharmacologically active molecule. The impurity was linked to certain synthetic routes, reagents, reaction conditions and potentially reused solvents. Not all valsartan products, manufacturers or batches were affected, and not all ARB medicines were recalled [2,11].
EMA initiated a formal review in July 2018, and FDA and national authorities coordinated testing, recalls and risk communication [2,10,11]. The WHO issued a medical product alert on 18 July 2018 [12]. These measures illustrate how a quality defect can require pharmacovigilance and regulatory coordination even when there is no conventional, temporally immediate adverse drug reaction.
Risk interpretation
An elevated nitrosamine level is an analytical finding, not a diagnosis of cancer in an exposed patient. Cancer risk estimates depend on impurity concentration, daily dose, exposure duration and toxicological assumptions; a hypothetical lifetime risk is not a directly observed incidence rate among exposed valsartan users. Epidemiological follow-up may be limited by incomplete batch histories and latency.
Regulators cautioned patients not to stop blood-pressure treatment abruptly without professional advice because uncontrolled hypertension or heart failure carries established immediate risk [10]. A recall communication should provide a safe replacement pathway while avoiding false reassurance or exaggerated individual cancer-risk certainty.
Why this belongs in a pharmacovigilance article
Quality defect handling intersects with case processing but is not reducible to it. A product complaint may concern impurity testing with no adverse event; an ICSR may report an event without any known quality defect. Where both exist, systems should link them while preserving their distinct regulatory pathways and evidence requirements.
11. Operational management of a nitrosamine-related product complaint
The initial record should capture manufacturer, product name, strength, dosage form, batch/lot number, expiry, dispensing pharmacy, country, supply dates and any available packaging photographs. Verify the actual national recall scope using regulator notices and the batch history. Do not label every generic valsartan tablet as contaminated because another manufacturer was recalled.
For a potential impurity exposure, record approximate daily dose and dates, possible interruptions, batch changes and whether a replacement product was supplied. Keep laboratory test results, certificates of analysis and supplier/manufacturing investigations separate from assumptions about a patient's exposure. If an adverse event is also reported, create or link the appropriate safety record and assess it on its clinical merits.
A meaningful governance trail should cover detection, quarantine and distribution control, health-hazard assessment, recall classification and notification, communication to professionals and patients, effectiveness checks, root-cause investigation, corrective and preventive actions and prevention of recurrence. These are quality-system functions with pharmacovigilance interfaces; applicable legal obligations and timelines depend on jurisdiction and event classification.
12. Routine pharmacovigilance: case follow-up by phenotype
| Suspected issue | Information that can change assessment | Common confounders |
|---|---|---|
| Symptomatic hypotension | BP trend, syncope, falls, diuretic changes, fluid losses | Sepsis, bleeding, arrhythmia, dehydration |
| Acute kidney injury | Baseline/serial creatinine, urine output, BP, renal imaging if done | NSAIDs, obstruction, infection, heart failure |
| Hyperkalaemia | Potassium repeat, ECG, renal function, supplements | Haemolysed sample, kidney disease, other RAAS drugs |
| Fetal exposure | Gestational dates, exposure timing, ultrasound, infant follow-up | Maternal disease, other medicines, obstetric factors |
| Angioedema | Airway findings, site, onset, prior episodes, co-exposures | ACE inhibitors, food/allergy, hereditary angioedema |
| Suspected impurity | Batch, supplier, assay, actual exposure dates, recall status | Incorrect lot attribution, unrelated symptoms |
These fields are recommended for clinical completeness, not substitutes for the minimum validity criteria for an ICSR. A report may be valid before all laboratory results or batch details become available.
Illustrative case: worsening kidney function
A patient with heart failure receiving valsartan and a loop diuretic develops diarrhoea and dizziness, followed by a marked creatinine increase. The report should distinguish baseline renal disease, acute fluid losses, blood-pressure changes and other medicines. A temporal association with valsartan supports further evaluation, not a conclusion that valsartan alone caused structural kidney injury. This is a teaching example, not a real patient report.
Illustrative case: recalled product without symptoms
A pharmacy identifies a recalled valsartan lot dispensed several months earlier. No adverse event is reported. This is primarily a quality complaint and exposure-tracing event, not an invented ICSR. If a patient subsequently reports a medical event, assess clinical validity, temporality and alternative causes, while linking the product investigation where appropriate. A hypothetical later cancer diagnosis would require especially careful attention to latency and exposure evidence, not automatic attribution.
13. Signal management and QPPV oversight
For ordinary adverse reactions, examine seriousness, expectedness, causality evidence, clinical phenotype, dose chronology, confounders and reporting obligations. For quality-related signals, add manufacturer, synthesis route, testing method, impurity identity, batch distribution and cumulative exposure assessment. These are overlapping but different analytical populations.
The QPPV should be able to trace the route by which serious adverse-event reports, quality defects, medical literature, supplier information and competent-authority communications reach appropriate functions. The evidence trail should demonstrate why a signal was validated, investigated, closed or escalated; how reference safety information and risk-management measures were considered; and how patients were protected while treatment continuity was maintained.
An increase in spontaneous reports after a recall announcement may reflect publicity and stimulated reporting. Without valid exposure denominators and a comparable ascertainment process, reporting counts cannot estimate incidence. Similarly, absence of cancer reports shortly after exposure cannot prove long-term absence of risk.
14. Regulatory learning from the valsartan crisis
The 2018 episode demonstrated that apparently routine changes to chemical synthesis and supplier networks can create unanticipated toxicological exposure. Regulatory responses expanded attention to nitrosamine risk assessment across many chemically synthesised medicines, rather than restricting concern to valsartan [2,11,13].
The scientific questions differ by stage: Is the impurity present? At what concentration? Which batches and patients were exposed? What toxicological threshold is relevant? What manufacturing control failed? What replacement treatment is available? A single clinical case narrative cannot answer all these questions. A successful system links analytical chemistry, pharmacovigilance, regulatory affairs, manufacturing quality and supply continuity.
15. Key takeaways
Valsartan's clinical value rests on specific evidence in hypertension, heart failure and post-infarction populations, not on the assumption that all RAAS blockers are interchangeable. VALIANT supports noninferiority to captopril in a defined post-MI population; Val-HeFT supports morbidity benefit without demonstrating overall mortality reduction; VALUE did not show superiority over amlodipine on its primary cardiac composite [5,7,9].
The most important predictable risks are fetal toxicity, symptomatic hypotension, renal-function deterioration and hyperkalaemia, modified by disease severity and concomitant medicines [1]. The 2018 nitrosamine crisis is a separate, major example of how manufacturing impurities can alter benefit–risk management and trigger recalls without changing the intended active ingredient's pharmacology [2,10–13].
References
- DailyMed. Valsartan tablets, US prescribing information, revised February 2026. https://www.dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=03af7d09-314a-fe85-e063-6294a90afa25&type=display
- US FDA. Recalls of angiotensin II receptor blockers including valsartan, losartan and irbesartan. https://www.fda.gov/drugs/drug-safety-and-availability/recalls-angiotensin-ii-receptor-blockers-arbs-including-valsartan-losartan-and-irbesartan
- DailyMed. Valsartan product pharmacology and clinical studies, US label. https://www.dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=947c5180-d38e-4d21-e053-2a95a90aaf75&type=display
- DailyMed. Valsartan tablets, older US label, revised June 2020. https://www.dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=5a816ea6-2645-bd6e-e063-6294a90a908b&type=display
- Julius S et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet. 2004;363:2022–2031. https://pubmed.ncbi.nlm.nih.gov/15207952/
- Weber MA et al. Blood pressure dependent and independent effects of antihypertensive treatment on clinical events in the VALUE Trial. Lancet. 2004;363:2049–2051. https://pubmed.ncbi.nlm.nih.gov/15207957/
- Cohn JN, Tognoni G. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med. 2001;345:1667–1675. https://doi.org/10.1056/NEJMoa010713
- Maggioni AP et al. Effects of valsartan on morbidity and mortality in patients with heart failure not receiving ACE inhibitors. J Am Coll Cardiol. 2002. https://pubmed.ncbi.nlm.nih.gov/12392830/
- Pfeffer MA et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med. 2003;349:1893–1906. https://doi.org/10.1056/NEJMoa032292
- EMA. Update on review of valsartan medicines following detection of impurity in active substance. 17 July 2018. https://www.ema.europa.eu/en/documents/press-release/update-review-valsartan-medicines-following-detection-impurity-active-substance_en.pdf
- EMA. Sartan medicines: companies to review manufacturing processes to avoid presence of nitrosamine impurities. 2019. https://www.ema.europa.eu/documents/press-release/sartan-medicines-companies-review-manufacturing-processes-avoid-presence-nitrosamine-impurities_pr.pdf
- WHO. Medical Product Alert N°4/2018: impurity discovered in valsartan. 18 July 2018. https://www.who.int/news/item/18-07-2018-medical-product-alert-n-4-2018--impurity-discovered-in-valsartan
- WHO. Information Note: Nitrosamine impurities. 20 November 2019. https://www.who.int/news/item/20-11-2019-information-note-nitrosamine-impurities
Regulatory Note
Educational review prepared 22 October 2026 from identified primary trial reports and regulatory sources. Authorised indications, paediatric ages, dose limits and interaction language may differ across products and jurisdictions; verify the currently marketed local product information. This article distinguishes pharmacological adverse reactions from manufacturing-quality defects and observed clinical outcomes from theoretical toxicological risk. Illustrative cases are not actual safety reports.